RLMD Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 15.42%, SMA50 11.7%, SMA200 104.31%). The stock’s 14-day RSI is 61.39 (firm momentum), while the ATR of 0.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -10.16% below its high and over 1813.48% above its low. Average 10-day trading volume of 1.77 million shares is in line with the 3-month average of 1.66 million, indicating normal recent market interest.

Relmada Therapeutics, Inc. has 33.19 million shares outstanding. The public float is 23.27 million shares, elevated short interest at 1.24% of float. This equals 401.31 thousand shares. The short ratio is 1.97 days. Institutional investors hold 92.16% of the float. Insiders own 2.9%. TRAVERSA SERGIO holds 1.30 million shares, Shenouda Maged has 800.00 thousand shares and Kelly Paul Edward has 502.30 thousand shares.

Relmada Therapeutics, Inc. generated EPS of -$1.80 over the past year. Five-year average earnings growth is 0.68%. Wall Street analysts project EPS growth of 33.29% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.15. Next year's EPS is expected at $22.65. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $8.00. The high target offers 262.6% upside. The low target suggests 52.67% downside. The mean target is $12.00. This offers 129.01% upside. Relmada Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 12, 2026, missed forecasts by 22.22%. The prior quarter beat by 92.86%. Over the last six quarters, Apple has recorded several small beats. These include -11.43% in March 27, 2025.

Relmada Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.09. This means the shares are trading above this model’s fair value.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) closed at $5.24 USD, losing -$0.22 (-4.03%) from the previous close of $5.46. The stock is currently mid-range between its 52-week high and low $0.55 and $8.00. With a market capitalization of about $549.62 million, Relmada Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 1.60 million shares, trading with heavier-than-usual volume. Headquartered in Coral Gables, FL, Relmada Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sergio Traversa, the company employs approximately 17 people and listed since June 20, 2014. Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Relmada Therapeutics, Inc. trades at a P/E ratio of -4.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.12 suggesting the stock is closer to book value. The P/FCF stands at -13.13, also below market averages.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares are down -18.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Relmada Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $35.67, suggesting 580.73% upside. Our AI forecast model points to short-term strength (2.67% over two weeks), a medium-term rise (76.15% over three months), and a longer-term gain (369.85% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Relmada Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.67%, with price expected at $5.38 by July 30, 2026, within a range of $4.97 to $5.77 3-Month Outlook: Projected rise of 76.15%, reaching $9.23 by October 12, 2026, with a range of $9.13 to $9.31. 1-Year Outlook: Projected gain of 369.85%, with price at $24.62 by July 16, 2027, within a range of $24.58 to $24.70.